7-氨基-1,2,3,4-四氢萘酚 | 214698-03-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 7-氨基-1,2,3,4-四氢萘酚
• 英文名称: 7-amino-1,2,3,4-tetrahydronaphthalen-1-ol
• 英文别名: 7-amino-1,2,3,4-tetrahydronaphthalene-1-ol；7-Amino-1-hydroxy-tetralin
• CAS: 214698-03-0
• 化学式: C₁₀H₁₃NO
• 分子量: 163.219
• InChiKey: NUDRGEJVHRQBJZ-UHFFFAOYSA-N

物化性质

• 熔点：
  91.7-91.8 °C
• 沸点：
  346.7±37.0 °C(Predicted)
• 密度：
  1.204±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2922299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 7-Amino-1,2,3,4-tetrahydronaphthol
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 7-Amino-1,2,3,4-tetrahydronaphthol
CAS number: 214698-03-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H13NO
Molecular weight: 163.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-氨基-1,2,3,4-四氢萘酚 在 碘 、 碳酸氢钠 作用下， 以 二氯甲烷 、 水 为溶剂， 生成
  参考文献：
  名称：

  2-炔基苯胺中的级联烷基迁移用于合成苯环多功能吲哚

  摘要：

  据报道，2-炔基苯胺通过芳香性破坏和重建过程进行级联烷基迁移。第一次烷基迁移是通过氧化和环化生成脱芳构化芳烃物种引发的，第二次烷基迁移是由恢复重排产物芳香性的力驱动的。该反应产生了一系列多官能化吲哚。

  DOI：

  10.1039/d3cc04815b
• 作为产物：
  描述：

  7-硝基-3,4-二氢-2H-1-萘酮 在 Pd-C sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 生成 7-氨基-1,2,3,4-四氢萘酚
  参考文献：
  名称：

  COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

  摘要：

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。

  公开号：

  US20110098311A1

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Spirobifluorene‐based Porous Organic Polymers as Efficient Porous Supports for Pd and Pt for Selective Hydrogenation
  作者：Mihaela Mirela Trandafir、Lidia Pop、Niculina D. Hӑdade、Ioana Hristea、Cristian Mihail Teodorescu、Frank Krumeich、Jeroen A. van Bokhoven、Ion Grosu、Vasile I. Parvulescu

  DOI：10.1002/cctc.201801247

  日期：2019.1.9

  Spirobifluorene‐based porous organic polymers (POP) were synthesized following two different protocols; the acetylenic coupling reaction conditions and the Sonogashira cross‐coupling reaction. These were utilized as support for the hydrogenation of a series of species containing unsaturated C=C and C=O bonds (4‐nitrostyrene, 4‐bromobenzophenone, acetophenone, 7‐nitro‐1‐tetralone and 1,2‐naphtoquinone

  螺环芴基多孔有机聚合物（POP）是根据两种不同的方案合成的；炔偶联反应条件和Sonogashira交叉偶联反应。这些被用来支持一系列含有不饱和C = C和C = O键的物种的加氢反应（4-硝基苯乙烯，4-溴二苯甲酮，苯乙酮，7-硝基-1-四氢萘酮和1,2-萘醌证实了它们的有效性）。通过铜催化方案制备的POP1完全不活泼，而含有钯的POP2-4则根据底物对金属的可及性表现出不同的活性。0.5重量％的Pd的进一步沉积导致活性和稳定的催化剂。它们很容易通过过滤分离，再分散后，连续十个循环可提供相同的性能。这项研究还通过比较Pd / POP与相同钯含量的Pd / C催化剂的行为，证明了载体在这些反应中的特定作用。Pt在这些载体上的沉积导致了亚纳米级的颗粒，并因此导致了仅由选择性差异反映的不同催化行为。
• MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
  申请人：Sheth Urvi

  公开号：US20120309758A1

  公开（公告）日：2012-12-06

  The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

  本发明涉及调节ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节蛋白，以及相关的组合物和方法。本发明还涉及使用这些调节剂治疗ABC转运蛋白介导的疾病的方法。
• [EN] COMPOUNDS HAVING SEROTONIN 5-HT17 RECEPTOR ANTAGONIST ACTIVITY AND MUSCARINIC M4 RECEPTOR AGONIST ACTIVITY AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS<br/>[FR] COMPOSES PRESENTANT UNE ACTIVITE ANTAGONISTE DU RECEPTEUR DE LA SEROTONINE 5-HT17 ET UNE ACTIVITE AGONISTE DU RECEPTEUR MUSCARINIQUE M4 ET UTILISATION DE CES COMPOSES POUR LE TRAITEMENT DES TROUBLES PSYCHOTIQUES
  申请人：MITSUBISHI PHARMA CORP

  公开号：WO2004087124A1

  公开（公告）日：2004-10-14

  The present invention relates to novel treatments for schizophrenia, based on the concept of identifying agents capable of selectively binding to the serotonin 5-HT7 and muscarinic M4 receptors and the use of such compounds in treating schizophrenia. The present invention also relates to novel amidine compounds for treating schizophrenia, a method of manufacturing such compounds, pharmaceutical formulations comprising said compounds, as well as medical uses and methods of treatment using said compounds.

  本发明涉及基于识别能够选择性结合到5-羟色胺5-HT7和肌碱M4受体的药剂，并将这类化合物用于治疗精神分裂症的新型治疗方法。本发明还涉及用于治疗精神分裂症的新型胺基化合物，一种制造这类化合物的方法，包含该化合物的药物配方，以及使用该化合物进行治疗的医疗用途和治疗方法。
• [EN] MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS<br/>[FR] MODULATEURS DE TRANSPORTEURS DE CASSETTE DE LIAISON A L'ATP
  申请人：VERTEX PHARMA

  公开号：WO2006002421A2

  公开（公告）日：2006-01-05

  The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

  本发明涉及ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节因子，其组合物和使用它们的方法。本发明还涉及使用这种调节剂治疗ABC转运蛋白介导的疾病的方法。